Current Rating Overview
MarketsMOJO currently assigns Lupin Ltd. a Mojo Score of 77.0, corresponding to a 'Buy' grade. This rating reflects a comprehensive evaluation of the company’s quality, valuation, financial trend, and technical indicators. The score represents a slight moderation from the previous 'Strong Buy' rating, which was held until 25 May 2026 when the Mojo Score decreased by 3 points from 80 to 77. Despite this change, the 'Buy' rating signals a positive outlook for investors seeking exposure to the Pharmaceuticals & Biotechnology sector through Lupin Ltd.
Quality Assessment
As of 08 June 2026, Lupin Ltd. maintains a 'good' quality grade, underpinned by its robust financial health and operational consistency. The company’s debt-to-equity ratio remains low at 0.11 times, indicating prudent leverage management and a strong balance sheet. This conservative capital structure supports sustainable growth and reduces financial risk, which is a favourable attribute for long-term investors.
The company’s operational performance further reinforces its quality standing. Net sales have grown at an annual rate of 13.02%, while operating profit has expanded by 34.70%, demonstrating effective cost management and revenue growth. Additionally, Lupin has reported very positive results for the last four consecutive quarters, with the most recent quarter (March 2026) marking record highs in net sales at ₹7,474.66 crores and profit after tax (PAT) at ₹1,560.39 crores. These figures highlight Lupin’s ability to consistently generate strong earnings and cash flow.
Valuation Perspective
The valuation grade for Lupin Ltd. is currently 'attractive'. The stock trades at a price-to-book value of 4.6, which, while elevated, is considered reasonable given the company’s strong return on equity (ROE) of 25.7%. This ROE level indicates efficient utilisation of shareholder capital to generate profits. Moreover, Lupin’s stock is trading at a discount relative to its peers’ historical valuations, offering investors a compelling entry point.
Over the past year, the stock has delivered a return of 13.71%, outperforming many midcap peers in the Pharmaceuticals & Biotechnology sector. Notably, the company’s profits have surged by 75.6% during the same period, resulting in a low PEG ratio of 0.2. This suggests that Lupin’s earnings growth is not fully priced into the stock, enhancing its appeal from a valuation standpoint.
Financial Trend and Performance
The financial trend for Lupin Ltd. is rated as 'very positive'. The company’s consistent quarterly earnings growth and strong profitability metrics underscore a healthy upward trajectory. The return on capital employed (ROCE) for the half-year ended March 2026 stands at an impressive 27.06%, reflecting efficient capital deployment and operational excellence.
Institutional investors hold a significant 47.03% stake in Lupin Ltd., signalling confidence from sophisticated market participants who typically conduct rigorous fundamental analysis. This high institutional ownership often correlates with greater stock stability and liquidity, which can be advantageous for retail investors.
Technical Analysis
From a technical standpoint, Lupin Ltd. is rated as 'mildly bullish'. The stock has experienced some short-term volatility, with a one-month decline of 3.35% and a three-month dip of 2.89%. However, the six-month and year-to-date returns remain positive at 7.98% and 7.24% respectively, indicating underlying strength. The one-day gain of 0.72% on 08 June 2026 further supports a cautiously optimistic technical outlook.
Investors should consider this mildly bullish technical stance as a signal that while the stock may face intermittent fluctuations, the overall trend remains supportive of further gains in the medium term.
Here's How Lupin Ltd. Looks Today
As of 08 June 2026, Lupin Ltd. presents a compelling investment case characterised by solid fundamentals, attractive valuation, positive financial trends, and supportive technical indicators. The company’s strong growth in net sales and profits, combined with prudent financial management and institutional backing, underpin the current 'Buy' rating.
For investors, this rating suggests that Lupin Ltd. offers a favourable risk-reward profile within the Pharmaceuticals & Biotechnology sector. The stock’s attractive valuation metrics relative to earnings growth and peer comparisons indicate potential for capital appreciation. Meanwhile, the company’s quality and financial strength provide a cushion against sector volatility and economic uncertainties.
Quarter after quarter, this Small Cap from the Lifestyle sector delivers without fail! Just added to our Reliable Performers with proven staying power. Stability meets growth here beautifully.
- - Consistent quarterly delivery
- - Proven staying power
- - Stability with growth
Investor Implications
Investors looking to build or enhance exposure to the pharmaceutical sector may find Lupin Ltd. an attractive option given its current 'Buy' rating. The company’s demonstrated ability to grow revenues and profits consistently, alongside a strong balance sheet and reasonable valuation, supports a positive medium-term outlook.
However, as with all equity investments, it is prudent to monitor sector dynamics, regulatory developments, and company-specific news that could impact performance. The mildly bullish technical rating suggests that while the stock is trending positively, short-term price fluctuations are possible.
Overall, Lupin Ltd.’s current rating by MarketsMOJO reflects a balanced view that combines solid fundamentals with reasonable valuation and technical support, making it a stock worth considering for investors seeking growth within the midcap pharmaceutical space.
Summary
To summarise, Lupin Ltd. is rated 'Buy' by MarketsMOJO as of 25 May 2026, with all financial and market data reflecting the stock’s position as of 08 June 2026. The company’s strong quality metrics, attractive valuation, very positive financial trends, and mildly bullish technical outlook collectively justify this rating. Investors should view Lupin Ltd. as a fundamentally sound and reasonably valued opportunity within the Pharmaceuticals & Biotechnology sector, offering potential for steady returns supported by robust earnings growth and institutional confidence.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
